 DARTMOUTH, Nova Scotia--BUSINESS WIRE--- IMV--IMV Inc. the Company or IMV TSX: IMV; NASDAQ: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and year ended December 31, 2020. Notwithstanding the challenges everyone faced in 2020, IMVs commitment to provide effective and well-tolerated immunotherapies to patients with hard-to-treat cancer resulted in significant progress 